Rubigen

Rubigen - General Information

A drug formerly used as an antipsychotic but now used primarily in the treatment of various movement disorders including tardive dyskinesia. Rubigen blocks uptake into adrenergic storage vesicles and has been used as a high affinity label for the vesicle transport system. [PubChem]

Pharmacology of Rubigen

Not Available

Additional information about Rubigen

Rubigen Indication: For the symptomatical treatment of hyperkinetic movement disorder.
Mechanism Of Action: Rubigen works mainly as a VMAT-inhibitor and as such promotes the early metabolic degradation of the neurotransmitter dopamine.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Tetrabenazine
Synonyms: Tetra benazin; Tetrabenazina [inn-spanish]; Tetrabenazinum [inn-latin]; Tetrabenzaine; Tetrabenzine
Drug Category: Adrenergic Uptake Inhibitors
Drug Type: Small Molecule; Approved

Other Brand Names containing Tetrabenazine: Nitoman; Regulin; Rubigen; Xenazine;
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of Rubigen: Tablet Oral
Chemical IUPAC Name: 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydropyrido[2,1-a]isoquinolin-2-one
Chemical Formula: C19H27NO3
Tetrabenazine on Wikipedia: https://en.wikipedia.org/wiki/Tetrabenazine
Organisms Affected: Humans and other mammals